The US Food and Drug Administration (FDA) has granted Fast Track Designation to Complement Therapeutics’ CTx001, the ...
In a recent study posted to the bioRxiv* pre-print server, researchers investigated the complement component 1q (C1q) binding and subsequent complement activation by neutralizing antibodies (nAbs) ...
Please provide your email address to receive an email when new articles are posted on . A protein known as granzyme K was recently shown to be a driver of inflammation by activating the complement ...
Dianthus Therapeutics Inc. has, appropriately, flowered in springtime. The Waltham, Mass.-based company emerged from stealth with $100 million in series A funding and lofty ambitions to rewrite the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback